Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsDysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegansThe sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismStriatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movementsStriatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Striatal neuroinflammation promotes Parkinsonism in ratsThe locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural studyThe role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned ratsStriatal glutamate release in L-DOPA-induced dyskinetic animalsPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingLRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesiasDopamine neuron stimulating actions of a GDNF propeptideChronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domainPharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's diseaseChemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingPresynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in ratsInvolvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesiaNeuronal Entropy Depends on the Level of Alertness in the Parkinsonian Globus Pallidus in vivoBotulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian ratsSpontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats.T-Lymphocyte Deficiency Exacerbates Behavioral Deficits in the 6-OHDA Unilateral Lesion Rat Model for Parkinson's Disease.Transcriptome analysis in a rat model of L-DOPA-induced dyskinesiaInteractions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's ratsPostsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat modelsLocal modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonismDopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
P2860
Q21129423-33A802AF-D153-4A71-9C88-5985496EBED2Q24324231-A5732828-5824-44D8-B926-0D5FFABCFE6AQ24614102-E7DF1E91-FFE8-4D02-BC61-B23E24519A53Q24632752-B1EC0D06-34AF-45CB-B0B1-B563A690FFA8Q26768220-22A4E5F2-D689-4787-84B9-B2CF8805FC08Q27324133-D9D1A4FE-C7CC-4D35-9A3F-2BB4E3935F6FQ27324174-C055FABD-D07E-4A4C-95AD-D5ECD035669DQ28475466-C144F50E-DAD2-4EB3-8CBD-0D3D7EA92E81Q28477041-FE158CCD-77DB-4885-B53C-9F04B230DC35Q28482094-5587781C-35A7-4E4B-8630-A123DF3E43B7Q28485942-788B1839-83BF-4149-916B-1FEEE71C8F54Q28582674-382B6B5E-7DE8-482C-8EB6-0E3646ACE1D8Q28602836-BF6F67E7-7A56-44CB-A7B7-DBC5CCECA1B6Q28748465-330F9C13-B1B7-43C1-B050-D49EE9E8E0A4Q30484170-BBEAE732-E832-4B64-9C0E-EBD7BAFFE2F6Q30594829-2E7F3E5B-3DB1-41D9-B9DF-A68D671F620EQ30653115-DBE73F22-AC0F-4C62-8931-F38BA03EFF26Q30665304-D6311E7A-73A1-486B-9D27-E1D92467FA75Q30836713-FA599B19-330F-483E-9C64-EE400EA27947Q33255884-1E20C6CB-8148-4C61-BE36-E008A8BAC6FCQ33285975-919A45D3-2F91-4AB6-A353-65524EB989EBQ33428476-5B741422-0FB8-4342-AFFE-3FE57221EECAQ33628372-8D3FF65D-C12A-49DA-8740-85697872A2D0Q33725654-21851B4B-9526-4F25-91F8-B81AF2D5CE65Q33801793-24BC75E1-0CCE-4A10-94DF-22675F511356Q33819387-9B217618-1AF9-4A03-B44C-F6E6D2818FD6Q33918393-F50E03A4-DDC5-482C-829B-4948D429D08BQ33931801-94CB6B9F-7991-45D9-B6DB-1FBCACBDCED6Q34044620-E2C50C86-329A-4862-8149-5A6C800AC869Q34105586-17435302-E1E6-47CC-9725-76DF83AFC0F0Q34131256-BCE1B5D4-C96D-4308-85CC-EEB50DFFBEBEQ34279877-99FD3CF7-218B-43AB-9B1C-72CF856E990DQ34392867-C694AB67-7CE5-4E83-88D3-132F916E18AEQ34400095-9B6ECDF2-09CE-4CB8-9830-EB2F3BF3DE1BQ34417485-BB9EE091-16D3-472D-9190-9762BB3BCFFFQ34783370-C8C1DCD8-C418-47E6-8978-570714718A17Q35000569-9DE3F455-222B-4D58-A581-67A8E5D3E731Q35003086-754C5148-15DF-4396-9CC4-79EA1E04FB0FQ35028568-400723DA-2F47-45FA-8DAD-F8101FDD6628Q35038040-EE00E1E9-23A1-41F6-94A8-E6D8E167D436
P2860
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacological validation of ...... model of Parkinson's disease.
@ast
Pharmacological validation of ...... model of Parkinson's disease.
@en
type
label
Pharmacological validation of ...... model of Parkinson's disease.
@ast
Pharmacological validation of ...... model of Parkinson's disease.
@en
prefLabel
Pharmacological validation of ...... model of Parkinson's disease.
@ast
Pharmacological validation of ...... model of Parkinson's disease.
@en
P2093
P921
P1476
Pharmacological validation of ...... t model of Parkinson's disease
@en
P2093
P304
P356
10.1046/J.0953-816X.2001.01843.X
P407
P577
2002-01-01T00:00:00Z